TH-302, a novel tumor hypoxia-selective treatment for patients with cancer {#s1}
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Tumor hypoxia has been shown to correlate with poor clinical prognosis due to both therapeutic treatment failure and hypoxia-induced prometastatic potential. A team of researchers from Threshold Pharmaceuticals have demonstrated that TH-302, an optimized hypoxia-activated prodrug, selectively targets the hypoxic regions of human xenograft tumors. "Targeting tumor hypoxia is an attractive strategy for the development of new and effective cancer therapies," says Jessica Difei Sun, the senior author of this study.

Sun and colleagues conducted the study by employing a panel of human tumor xenograft models, which covered a broad range of specific tumor types. "Preclinical mouse models of cancer have been shown to recapitulate the architecture of the tumor microenvironment and the prevalence of subregional hypoxia. The use of human tumor xenografts for the preclinical evaluation of new anticancer drugs is an integral part of drug discovery strategies in which specific characteristics of tumor lines can be used to guide future clinical development," explains Sun.

In this study, 11 models were employed and each had its characteristic sensitivity or resistance to treatment with TH-302, as well as characteristic histology and immunohistochemistry for hypoxia, vasculature, cell proliferation, and DNA damage after TH-302 treatment. TH-302 showed antitumor activity as a single agent across various tumor types in these xenograft models, and this activity was correlated with total drug exposure. Significant inhibition of tumor growth was observed in 8 of 11 xenograft models examined, but TH-302 had low activity in three models. In these three pancreatic xenograft models, the low activity of TH-302 was consistent with their tumor microenvironment phenotype of minimal hypoxia, which was measured by pimonidazole staining.

In addition, the results in this study shed light on the potential use of a hypoxia biomarker to guide the selection of patients for TH-302 treatment. "The strong correlation between the magnitude of tumor hypoxia as measured by pimonidazole staining and TH-302 efficacy could serve as the basis for clinical trials that include analysis of patient biopsies stained with pimonidazole and the subsequent comparison with TH-302 efficacy," Sun explains. "I also hope to get a chance to collaborate with the researchers and scientists in China in the area of cancer drug discovery and development," she adds.

The results described in this study support the hypoxic selectivity of TH-302 *in vivo*, as well as the use of hypoxia biomarkers to profile patient biopsies and guide patient selection for therapy with TH-302. TH-302 is currently in clinic trials for cancer treatment. In the near future, TH-302 may become a novel treatment for cancer patients, especially if the patients treated with TH-302 are first selected using hypoxia biomarkers.
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Sixty mg/kg of pimonidazole was intraperitoneally dosed to the animal, and the tumor was harvested 1 h later. Hypoxic cells (brown) were detected by immunoperoxidase staining of pimonidazole in a formalin-fixed, paraffin-embedded section. The gradient of increasing immunostaining for hypoxic cells was noted from the blood vessel (arrow) to necrotic region (asterisk). Scale bar, 100 µm. *(Courtesy of Jessica Sun and Charles Hart, Threshold Pharmaceuticals, South San Francisco, California, CA 94080, USA)*](cjc-31-04-167-g001){#cjc-31-04-167-g001}
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